<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01471288</url>
  </required_header>
  <id_info>
    <org_study_id>88498</org_study_id>
    <nct_id>NCT01471288</nct_id>
  </id_info>
  <brief_title>Effect of Carum Carvi on Thyroid Hormones and TSH Level</brief_title>
  <official_title>Evaluation of the Effect of Carum Carvi on Levels of Plasma Thyroid Hormones and TSH Level in Patients on Thyroid Hormone Therapy and Normal Controls.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mashhad University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmaceutical Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mashhad University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carum Carvi has been frequently used in traditional medicine for a variety of disease ranging
      from dyspepsia to Alzheimer's disease.We observed high TSH levels in few patients with
      thyroid cancer who receiving Carum Carvi despite being on suppressive dose of levothyroxin.
      TSH level returned to normal after discontinuation of the Carum carvi. This observation led
      to a pilot study for evaluation of the effect of carum carvi on thyroid function.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Thyroid and thyrotropin values from baseline at 2 and 6 weeks</measure>
    <time_frame>0-2-6 Weeks</time_frame>
    <description>TSH, Free T4, Free T3, T4RIA and T3RIA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of hypothyroidism index from baseline at 2 and 6 weeks</measure>
    <time_frame>0,2 and 6 weeks</time_frame>
    <description>Hypothyroidism Index</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Thyroid Cancer Patients</condition>
  <arm_group>
    <arm_group_label>Group3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Normal controls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal controls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hypothyroid patients taking levothyroxin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Hypothyroid patients taking levothyroxin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carum Cravi</intervention_name>
    <description>40mg/kg of body weight</description>
    <arm_group_label>Group3</arm_group_label>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Group4</arm_group_label>
    <arm_group_label>Group2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65

          -  Hypothyroid patients under treatment with levothyroxin

          -  Normal euthyroid patients with no goiter

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  Severe lung or gasterointestinal disease

          -  Heart failure or renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seyed Rasoul Zakavi, MD. IBNM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nuclear Medicine Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Ramezani, Ph.D., Pharm.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pharmaceutical Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seyed Rasoul Zakavi, MD,IBNM</last_name>
    <phone>+98-511-8022729</phone>
    <email>zakavir@mums.ac.ir</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zohre Mousavi, MD, IBE</last_name>
    <phone>+98-8599359</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nuclear Medicine Department, Ghaem Hospital</name>
      <address>
        <city>Mashhad</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Zohre Mousavi, MD,IBE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fateme Khani</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maryam Naghibi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2011</study_first_submitted>
  <study_first_submitted_qc>November 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2011</study_first_posted>
  <last_update_submitted>November 14, 2011</last_update_submitted>
  <last_update_submitted_qc>November 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Seyed Rasoul Zakavi</name_title>
    <organization>Nuclear Medicine Research Center</organization>
  </responsible_party>
  <keyword>well differentiated thyroid cancer</keyword>
  <keyword>Carum Carvi</keyword>
  <keyword>Normal controls</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

